Joanne Quan, MD joined Mirum in 2024 as chief medical officer with responsibility for clinical development, clinical operations, and safety. Joanne has nearly three decades of experience developing novel therapeutics, including those for rare diseases.
Prior to Mirum, she served as chief medical officer at Nuvig Therapeutics. From 2018-2021, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc., and subsequently, UCB),. Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis.
Joanne received a BA in molecular biology at the University of California, Berkeley and an MD at Stanford University School of Medicine. She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington.
What is Joanne Quan's net worth?
The estimated net worth of Joanne Quan is at least $261,435.72 as of January 17th, 2025. Dr. Quan owns 5,649 shares of Mirum Pharmaceuticals stock worth more than $261,436 as of March 27th. This net worth evaluation does not reflect any other assets that Dr. Quan may own. Learn More about Joanne Quan's net worth.
How do I contact Joanne Quan?
The corporate mailing address for Dr. Quan and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Joanne Quan's contact information.
Has Joanne Quan been buying or selling shares of Mirum Pharmaceuticals?
In the last ninety days, Joanne Quan has sold $319,598.34 in Mirum Pharmaceuticals stock. Most recently, Joanne Quan sold 6,969 shares of the business's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $45.86, for a transaction totalling $319,598.34. Following the completion of the sale, the insider now directly owns 5,649 shares of the company's stock, valued at $259,063.14. Learn More on Joanne Quan's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 3/17/2025.
